Shots:

• Takeda exercised its option to acquire Maverick for up to $525M up front as well as development and regulatory milestones including Takeda’s current equity stake and Maverick debt. The acquisition is expected to finalize in Q1’21
• The acquisition will expand Takeda’s I-O portfolio with the addition of two development candidates (MVC-101 & MVC-280) and Maverick’s T-cell engagers COBRA platform- specifically designed to target solid tumor
• The acquisition 2017 collaboration of the companies to develop conditionally active T-cell engager therapies- in which Takeda received an equity stake and an exclusive right to acquire Maverick after 5yrs.

 ­ Ref: Takeda | Image: Maverick